Answers are grounded in this paper and cite their sources.
Background: Patient assistance programs (PAP) have been established for biologic disease modifying therapies such as etanercept to improve patient knowledge and compliance and provide a means for follow-up. The information collected through these programs is a potential data source to determine patient characteristics, patient outcomes, treatment adherence and reimbursement practices of individuals prescribed biologic disease modifying therapies.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: